- Protein Name
- Abelson tyrosine-protein kinase 2
- Gene Name
- ABL2
- Organism
-
Homo sapiens
- Function
- Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
17 |
3 |
12.0 |
| AAS |
17 |
5 |
6.5 |
| MT3 |
23 |
7 |
15.0 |
| LBP |
11 |
4 |
7.5 |
| ATP |
20 |
6 |
14.0 |
| DEF |
15 |
15 |
15.0 |
| DFG |
18 |
5 |
14.5 |
| CMP |
12 |
3 |
10.0 |
| EDI |
2 |
2 |
2.0 |
| DRS |
16 |
6 |
9.0 |
| PDIG |
2 |
2 |
2.0 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
AAS site |
MT3 site |
LBP site |
ATP site |
DEF site |
DFG site |
CMP site |
PMP site |
EDI site |
DRS site |
PDIG site |
PIF site |
| Total Druggable Structures per Site |
2 |
1 |
1 |
0 |
2 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
|
2XYN
|
17 |
7 |
23 |
11 |
17 |
15 |
14 |
3 |
0 |
2 |
9 |
2 |
0 |
|
3HMI
|
12 |
0 |
7 |
0 |
13 |
0 |
15 |
10 |
0 |
0 |
0 |
0 |
0 |
|
3GVU
|
17 |
17 |
0 |
0 |
20 |
0 |
0 |
11 |
0 |
0 |
16 |
0 |
0 |
|
AFP42684
|
0 |
0 |
0 |
0 |
0 |
0 |
18 |
12 |
0 |
0 |
0 |
0 |
0 |